Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Johnson & Johnson (JNJ) Frday announced data from three studies highlighting clinical efficacy of Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) in maintenance regimens.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1132012708-0d3f8f4b04c14405aa72e54940ab6a0e-3064dc565912458a94297c60b3d609e7.jpg "Is a Career in Investment Banking Worth It?")
:max_bytes(150000):strip_icc():format(jpeg)/KraftCadburyHostileTakeover-56143341d0004032a1cdb65ec3c2859b.jpg "What Are Some Top Examples of Hostile Takeovers?")
